Listen to the Latest Audiobook Releases of The Altascientist

Delve deeper into the critical processes behind early phase drug development with audio versions of The Altascientist, written by our experts with you in mind:

Issue 31 — The Advantages of Conducting Early Phase Clinical Research in Canada Find out you can accelerate your early phase clinical research by six to nine weeks in comparison with trials conducted in the U.S. Listen to the audiobook >>>	Issue 32 — A Changing Paradigm for Non-rodent Species in Nonclinical Safety Studies Discover the increasing body of evidence that supports the use of miniature swine as a viable option for your small and large molecule studies. Listen to the audiobook >>>​​​
Issue 33 — CNS Drug Development: Integrated Solutions Lessen Complexity Hear about the complexities of CNS drug development programs and how an integrated CRO/CDMO can help move your molecule seamlessly from one phase to the next. Listen to the audiobook >>>	In Case You Missed It:  Issue 30 — The Evolution and Advancement of LCMS in Drug Development Learn how the latest LC-MS advancements ensure accurate and precise data delivery in your drug development program. Listen to the audiobook >>>

This presentation shares a highly efficient method for determining antisense oligonucleotides (ASOs) in human blood. 

The technique combines Mitra® VAMS and hybridization LC-MS/MS, revolutionizing ASO quantification. Its key advantage is using Mitra® VAMS for remote sampling, enabling convenient and accurate data collection from micro samples. This method creates possibilities for decentralized clinical trials, facilitating research and development. 
 

We invite you to explore the potential of this bioanalytical workflow and its potential.

WATCH PRESENTATION

Speak with one of our bioanalytical experts to find out how we can support you.  

You may also be interested in the below resources:

Webpages:
• Microsampling Capabilities
• Oligonucleotide Capabilities         
• The Altascientist: Microsampling in Drug Development

Unlocking New Horizons

The FDA recently published a first-ever draft guidance on clinical development requirements for psychedelic drugs. 

Join Altasciences’ panel of experts as they provide an in-depth review of the guidance and valuable insights into the areas where further methodological adaptations to study designs may be necessary. These adaptations play a pivotal role in accurately assessing the safety, pharmacology, and efficacy of groundbreaking psychedelic compounds developed for specific medical applications.

LISTEN NOW

You may also be interested in the following:

•    Webpage: CNS Drug Development Solutions
•    Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
•    Webinar: Practical Approaches to Conducting Early Clinical Trials with Psychedelics

On June 15, our team took time to celebrate Altasciences, and how we move in unison to help you bring better drugs to the people who need them, faster.

Every day, and especially on Altasciences Day, I feel a great sense of appreciation and gratitude—for our talented experts who help build our business, as well as for YOUR ongoing trust and partnership.

Together, we change lives. And I can’t thank you enough for taking us along on your innovative, life-saving journey.

It is with pride that I share with you a photo album from our Altasciences Day celebrations.

See the photo album.

Thank you again,

Chris Perkin
CEO, Altasciences

The process of biologic drug development, from lead molecule identification to approval, can be long and complicated. Altasciences is here to help streamline the process. From discovery to preclinical, clinical, and beyond, Altasciences accelerates decision-making by offering expert guidance and synchronized early phase services to reduce timelines by up to 40%. With Altasciences, your entire program is managed by one organization and overseen by a single, cross-functional program manager to quickly and seamlessly advance your large molecule, and help you get your therapies to the people who need them, faster.

Download now.

You may also be interested in the following:
- Blog: Four Key Steps to Optimizing a Large Molecule Bioanalytical Program.
- Fact Sheet: Biologics/Biosimilars.
- Video: Quick Chat with Dr. Lynne Le Sauteur – The Benefits of Large Molecule Bioanalysis with Altasciences.

Fewer Hand-Offs for Shorter Timelines and Reduced Costs

Imagine the convenience of having a single point of contact guiding you through each step of drug development, from preclinical to early-phase clinical studies. When you partner with Altasciences, our program managers work closely with you from the get-go to understand your unique needs and objectives, and deliver tailored solutions that meet your requirements.

Our streamlined approach and efficient coordination ensure seamless integration of activities, optimizing resources and maximizing productivity.

Explore our fact sheet to discover the power of centralized program management with Altasciences.

Ready to get started? Schedule a conversation with one of our experts.

You may also be interested in these insightful resources:
      •   Webinar: The Path Forward, Altasciences' Approach to Project Management
      •   Video: The Benefits of Conducting a Clinical Trial in Canada
      •   Webpage: CRO Services For Clinical Research